PATHOGENETIC ROLE OF SURFACTANT PROTEIN B IN THE FORMATION OF PULMONARY PATHOLOGY IN ANIMALS WITH STREPTOZOTOCIN-INDUCED DIABETES
DOI:
https://doi.org/10.11603/mcch.2410-681X.2022.i4.13568Keywords:
streptozotocin-induced diabetes, surfactant protein BAbstract
Introduction. Nowadays, most researchers consider the lungs to be one of the main targets of diabetes mellitus. According to the literature data, pulmonary surfactants, particularly surfactant protein B play the leading role in the pathogenesis of respiratory diseases.
The aim of the study – to establish the pathogenetic role of surfactant protein B (SP-B) in the formation of lung pathology in animals with streptozotocin-induced diabetes.
Research Methods. The experiments were performed on 88 white male Wistar rats weighing 170–210 g. Animals were divided into three groups: 1 – intact (n=10); 2 – control (n=40); 3 – experimental (n=38) with a model of diabetes mellitus, which was reproduced by intraperitoneal injection of streptozotocin by “Sigma” company (USA), diluted in 0.1 M citrate buffer with a pH of 4.5, at a rate of 60 mg/kg body weight. The control group of animals received an intraperitoneal injection with an equivalent dose of 0.1 M citrate buffer solution with a pH of 4.5. SP-B content in blood serum was determined by Rat enzyme-linked immunosorbent assay (ELISA) kit (Elabscience, the USA) 14, 28, 42, and 70 days after streptozotocin injection.
Results and Discussion. Biochemical studies of blood serum showed an increase in SP-B levels in animals with streptozotocin-induced diabetes at all stages of the research. In particular, serum SP-B levels increased by 8.5 % in 14 days, 37.0 % in 28 days, 54.2 % in 42 days and 74.5 % in 70 days compared to the control group of animals.
Conclusions. During the entire study period, streptozotocin-induced diabetes is accompanied by an increase of surfactant protein B levels in the blood serum which plays a key role in the pathogenesis of lung injury in this pathology.
References
Papinska, A.M., Soto, M., Meeks, C.J., & Rodgers, K.E. (2016). Long-term administration of angiotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathological remodeling. Pharmacol. Res., 107, 372-380. DOI:10.1016/j.phrs.2016.02.026.
Rajasurya, V., Gunasekaran, K., & Surani, S. (2020). Interstitial lung disease and diabetes. World Journal of Diabetes, 11 (8), 351-357. DOI: 10.4239/wjd.v11.i8.351.
Simo, R., & Lecube, A. (2020). Looking for solutions to lung dysfunction in type 2 diabetes. Ann. Transl. Med., 8 (8), 521. DOI: 10.21037/atm.2020.03.225
Kuziemski, K., Slominski, W., & Jassem, E. (2019). Impact of diabetes mellitus on functional exercise capacity and pulmonary functions in patients with diabetes and healthy. BMC Endocrine Disorders, 19, 2. DOI: 10.1186/s12902-018-0328-1.
Zheng H, Wu J, Jin Z, Yan L-J. (2017). Potential biochemical mechanisms of lung injury in diabetes. Aging and Disease, 1 (8), 7-16. DOI: 10.14336/AD.2016.0627
Chen, X.-F., Yan, L.-J., Lecube, A., Tang, X.. (2020). Editorial: Diabetes and obesity effects on lung function. Fronties in Endocrinology, 11 (462), 1-2. DOI: 10.3389/fendo.2020.00462.
Depicolzuane, L., Phelps, D.S., Floros, J. (2022). Surfactant protein – a function: Knowledge gained from SP-A knockout mice. Frontiers in Pediatrics, 9, 799693. DOI: 10.3389/fped.2021.799693.
Martinez-Calle, M., Olmeda, B., Dietl, P., Frick, M., Perez-Gil, J. (2018). Pulmonary surfactant protein SP-B promotes exocytosis of lamellar bodies in alveolar type II cells, FASEB J., 32 (8), 4600-4611. DOI:10.1096/fj.201701462RR.
Hobi, N., Giolai, M., Olmeda, B., Miklavc, Р., Felder, E., Walther, P. (2016). A small key unlocks a heavy door: The essential function of the small hydrophobic proteins SP-B and SP-C to trigger adsorption of pulmonary surfactant lamellar bodies. Biochimica et Biophysica Acta., 1863, 2124-2134. DOI: http://dx.doi.org/10.1016/j.bbamcr.2016.04.028
Lopez-Rodriguez, E., Perez-Gil, J. (2014). Structure-function relationships in pulmonary surfactant membranes: From biophysics to therapy. Biochimica et Biophysica Acta., 1838, 1568-1585. DOI: htlp://dx.doi.org/10.1016/j.bbamem.2014.01.028.
Agostoni, P., Banfi, C., Brioschi, M., Magri, D., Sciomer, S., Berna, G. et al. (2011). Surfactant protein В and RAGE increases in the plasma during cardiopulmonary bypass: a pilot study. Eur. Respir. J., 37, 841-847. DOI: 10.1183/09031936.00045910.
Robichaud, N.A.S., Khatami, M.H., Saika-Voivod, I., Booth, V. (2019). All-atom molecular dynamics simulations of dimeric lung surfactant protein В in lipid multilayers. Int. J. Моl. Sci., 20 (16), 3863. https://doi.org/10.3390/ijms20163863.
Magri, D., Mariotta, S., Banfi, C., Ricotta, A., Onofri, A., Ricci, A. et al. (2013). Opposite behavior of plasma levels surfactant protein type В and receptor for advanced glycation end products in pulmonary sarcoidosis. Respiratory Medicine, 107, 1617-1624. DOI: htlp://dx.doi.org/10.1016/j.rmed.2013.07.019.
Nguyen, A.B., Rohatgi, A., Garcia, C.K., Ayers, C.R., Das, S.R., Lakoski, S.G. et al. (2011). Interactions between smoking, pulmonary surfactant protein B, and atherosclerosis in the general population: The Dallas Heart Study. Arterioscler. Thromb. Vasc. Biol., 31 (9), 2136-2143. DOI:10.1161/ATVBAHA. 111.228692.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Medical and Clinical Chemistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
